Lipid Nanoparticle Library Screen Reveals Lymphatic Endothelial Cell-Targeting Lipid Nanoparticle for Delivering Vascular Endothelial Growth Factor C mRNA after Lymphatic Injury

Nov 21, 2025ACS nano

Screening Lipid Nanoparticles Identifies One That Delivers Growth Factor mRNA to Lymphatic Vessel-Lining Cells After Injury

AI simplified

mRNA Technology on OpenScience ↗PubMed ↗DOI ↗OA ↗

Abstract

A single dose of VEGFC mRNA delivered via LNP7 resulted in enhanced lymphatic function for up to 14 days in a mouse model of lymphatic injury.

Lymphatic dysfunction can lead to lymphedema, a condition with no current cure.
A library of 150 lipid nanoparticles was screened to identify those with high uptake in lymphatic endothelial cells (LECs).
Several LNP formulations were validated for their effectiveness in delivering functional mRNA to LECs.
The lead formulation, LNP7, was loaded with VEGFC mRNA to assess its therapeutic effects.
Delivery of VEGFC mRNA via LNP7 resulted in increased LEC proliferation at the injury site.

AI simplified

Dysfunction of the lymphatic system following injury, disease, or cancer treatment can lead to lymphedema, a debilitating condition with no cure. Advances in targeted therapy have shown promise for treating diseases where conventional therapies, including broad-spectrum chemotherapy, surgical interventions, and palliative care, have often failed to achieve durable responses. As lymphatic vessels have recently emerged as a therapeutic target, nucleic acid delivery via nanoparticles to lymphatic endothelial cells (LECs) has been studied utilizing lymphatic drainage; however, there are no approaches to modulate the chemical compositions of lipid nanoparticles (LNPs) to optimize LEC specificity. To identify an LNP that effectively delivers mRNA to LECs after intradermal (ID) injection, we screened a library of 150 LNPs in total spread out over 3 screening rounds. The 150 formulations had a variety of chemical compositions and were assessed for both self-assembly and deliveryto LECs. We identified and validated several LNP formulations optimized for high LEC uptake when administered ID and compared their efficacy for delivery of functional mRNA with that of free mRNA and mRNA delivered with a commercially available MC3-based LNP (Onpattro). The lead LEC-LNP was then loaded with VEGFC mRNA to test the therapeutic advantage of this LEC enrichment (namely, LNP7) for treating a mouse tail lymphatic injury model. A single dose of VEGFC mRNA delivered via LNP7 resulted in enhanced LEC proliferation at the site of injury and an increase in lymphatic function up to 14 days postsurgery. Our results suggest a therapeutic potential of VEGFC mRNA using lymphatic-enriched LNP delivery for alleviating lymphatic dysfunction observed during lymphatic injury and could provide a promising approach for targeted and transient lymphangiogenic therapy. in vivo

Full Text

Full text is available at the source.

View full text (PDF) ↗View full text ↗

Lipid Nanoparticle Library Screen Reveals Lymphatic Endothelial Cell-Targeting Lipid Nanoparticle for Delivering Vascular Endothelial Growth Factor C mRNA after Lymphatic Injury

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the mrna technology brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the mrna technology brief